AtoCap
Latest round
- Seed
Last raised
- Sep 2015
Total raised
- $0.9M
Investors
- 2
About AtoCap
AtoCap Ltd is a pharmaceutical company that specializes in developing innovative microencapsulation technologies to enhance drug delivery for recurrent urinary tract infections (UTIs).AtoCap Ltd focuses on advanced microencapsulation technologies and was founded by Eleanor Stride and Mohan Edirisinghe. The company is headquartered in London, UK, with a focus on developing solutions for chronic urinary tract infections.42 million post-money.AtoCap specializes in innovative microencapsulation technologies designed to enhance the delivery of pharmaceuticals, particularly targeting the treatment of recurrent and chronic urinary tract infections (UTIs). Their flagship product, CapFuran®, utilizes a proprietary electro-hydrodynamic processing method to encapsulate a combination of generic antibiotics into multi-layered capsules. This advanced formulation allows for both immediate and sustained release of the drug, ensuring targeted delivery to affected areas in the body, specifically within the bladder. The product is engineered to effectively combat uropathogenic bacterial species, including E. coli, through a time-release mechanism. AtoCap's solutions are primarily aimed at healthcare providers and institutions dealing with a substantial patient population, particularly among the elderly, who are significantly affected by UTIs.AtoCap generates revenue through direct sales of its microencapsulation products, notably CapFuran®, to healthcare providers and institutions specializing in urology and infectious diseases. The company's transaction structure is based on B2B relationships, where healthcare providers procure these products to enhance their treatment offerings for patients suffering from recurrent UTIs. Pricing plans are structured based on the volume of product ordered, allowing for tailored solutions that meet the specific needs of different healthcare facilities. As the market for targeted antibiotic therapies is robust, particularly given the rising prevalence of UTIs worldwide, AtoCap's revenue model capitalizes on the demand for effective, innovative treatment options. The company is exploring expansion into new markets across North America and Asia by 2016, focusing on regions with high demand for urological health solutions.
Who invested in AtoCap
2 investors across 1 round
See all investors in AtoCap
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Sep 1, 2015
Amount
$0.9M
Investors
Questions about AtoCap
Who invested in AtoCap?
AtoCap has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AtoCap raised?
AtoCap has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AtoCap last raise money?
AtoCap's most recent round on record is a Seed, in Sep 2015.
What does AtoCap do?
AtoCap Ltd is a pharmaceutical company that specializes in developing innovative microencapsulation technologies to enhance drug delivery for recurrent urinary tract infections (UTIs).
Where is AtoCap headquartered?
AtoCap is headquartered in London, UK.
Which VCs invest in companies like AtoCap?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back pharmaceuticals companies at AtoCap's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Seed
Raising like AtoCap? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.